Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Terminated 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Tumor-Agnostic 1Gastrointestinal 1

Conditions

Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Colorectal Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Has results × adagrasib × Clear all
NCT06024174 2025-07-22

A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Terminated
5 enrolled 9 charts
GastrointestinalThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT04418661 2025-05-29

Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies

Sanofi

Phase 1/2 Terminated
65 enrolled 32 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT04685135 2025-01-22

KRYSTAL-12

Mirati Therapeutics Inc.

Phase 3 Active not recruiting
453 enrolled 20 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡